Twist Bioscience (0ME) Price & Analysis

3 Followers

0ME Stock Chart & Stats

€129.45

-€1.16(-1.43%)

At close: Jul 24 4:00 PM EDT

€129.45

-€1.16(-1.43%)

Day’s Range― - ―

52-Week Range€21.69 - €183.50

Previous CloseN/A

Volume5.00

Average Volume (3M)38.00

Market Cap

€8.95B

Enterprise Value€6.35B

Total Cash (Recent Filing)€166.84M

Total Debt (Recent Filing)€93.59M

Price to Earnings (P/E)―

Beta1.09

Next Earnings

Nov 13, 2026

EPS Estimate

-0.34

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.22

Shares Outstanding65,832,420

10 Day Avg. Volume36

30 Day Avg. Volume38

Financial Highlights & Ratios

PEG Ratio0.34

Price to Book (P/B)3.56

Price to Sales (P/S)4.47

P/FCF Ratio-22.25

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€141.55

Price Target Upside9.35% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering11

EPS Forecast (FY)-1.19

Revenue Forecast (FY)€487.38M

Bulls Say, Bears Say

Bulls Say

Revenue GrowthSustained revenue growth across 14 consecutive quarters indicates expanding customer demand rather than a single-period surge. Continued adoption across synthetic DNA, NGS, therapeutics, and diagnostics can broaden the company’s commercial base and support durable scale.

Manufacturing Efficiency And MarginsMaterial reductions in manufacturing costs, waste, and turnaround time show that the silicon-based platform is generating operating efficiencies as volume increases. These improvements can support margin durability, faster customer delivery, and better incremental economics.

AI-Enabled Protein Discovery PositioningThe Anthropic engagement validates Twist’s role between computational protein design and laboratory testing, a structurally growing workflow. Repeat work from AI-enabled discovery customers could expand demand for high-throughput synthesis and strengthen platform relevance.

Bears Say

Persistent Cash BurnNegative operating and free cash flow means the business has not yet funded its operations internally, despite improving revenue and margins. Continued cash burn can require additional financing and limits flexibility until growth converts into sustainable positive cash generation.

Ongoing Operating LossesTwist remains materially unprofitable, with large operating losses and a recent adjusted EBITDA deficit. Management’s breakeven target is prospective rather than achieved, so execution on expense control and operating leverage remains essential to establish durable profitability.

Competitive And Pricing PressureCompetitive actions and discounting could pressure average selling prices and alter the mix of sequencing and protein business. Even if current effects are limited, sustained pricing pressure would reduce the benefit of volume growth and make margin expansion harder to maintain.

Twist Bioscience News

Twist Bioscience price target raised to $190 from $115 at TD Cowen

TD Cowen raised the firm’s price target on Twist Bioscience (TWST) to $190 from $115 and keeps a...

10h ago

TWST

Twist Bioscience price target raised to $205 from $120 at Canaccord

Canaccord raised the firm’s price target on Twist Bioscience (TWST) to $205 from $120 and keeps a Buy...

2d ago

TWST

Twist Bioscience initiated with a Hold at Jefferies

Jefferies initiated coverage of Twist Bioscience (TWST) with a Hold rating and $150 price target Twist is a...

6d ago

TWST

Twist Bioscience price target raised to $215 from $112 at Barclays

Barclays raised the firm’s price target on Twist Bioscience (TWST) to $215 from $112 and keeps an Overweight...

7d ago

TWST

Twist Bioscience falls -12.7%

Twist Bioscience (TWST) is down -12.7%, or -$26.00 to $179.00. Published first on TheFly – the ultimate source...

7d ago

TWST

Twist Bioscience price target raised to $212 from $107 at Guggenheim

Guggenheim raised the firm’s price target on Twist Bioscience (TWST) to $212 from $107 and keeps a Buy...

12d ago

TWST

Twist Bioscience price target raised to $190 from $160 at Leerink

Leerink analyst Puneet Souda raised the firm’s price target on Twist Bioscience (TWST) to $190 from $160 and...

14d ago

TWST

Twist Bioscience rises 6.9%

Twist Bioscience (TWST) is up 6.9%, or $10.88 to $169.38. Published first on TheFly – the ultimate source...

19d ago

TWST

White House moves to take control of N.I.H. grants, NY Times reports

The White House has begun drafting a new executive order that could further cement President Trump’s ability to...

22d ago

DHR

Twist Bioscience price target raised to $160 from $120 at Leerink

Leerink analyst Puneet Souda raised the firm’s price target on Twist Bioscience (TWST) to $160 from $120 and...

26d ago

TWST

Twist Bioscience Rated Sell as Analyst Cites Limited Strategic Upside from Lilly TuneLab Deal; $45 Price Target Reaffirmed

Analyst Hamed Khorsand from BWS Financial maintained a Sell rating on Twist Bioscience and keeping the price target...

25d ago

TWST

Cathie Wood Buys $3.6M of HOOD, Sells $2.9M of 2 High-Growth Stocks – September 5

Cathie Wood-led ARK Invest made several notable trades on Friday, September 4, with Robinhood Markets ($HOOD), an online...

1M ago

MRK

TEM

Twist Bioscience Registers Invenra Share Resale Prospectus

An update from Twist Bioscience ( ($TWST) ) is now available. Twist Bioscience Corporation has filed a prospectus...

2M ago

TWST

Twist Bioscience tapped to validate Anthropic AI proteins

Twist Bioscience ( ($TWST) ) has issued an announcement. On August 18, 2026, Anthropic announced results from a...

2M ago

TWST

0ME FAQ

What was Twist Bioscience Corp’s price range in the past 12 months?

Twist Bioscience Corp lowest stock price was €21.69 and its highest was €183.50 in the past 12 months.

What is Twist Bioscience Corp’s market cap?

Twist Bioscience Corp’s market cap is €8.95B.

When is Twist Bioscience Corp’s upcoming earnings report date?

Twist Bioscience Corp’s upcoming earnings report date is Nov 13, 2026 which is in 31 days.

How were Twist Bioscience Corp’s earnings last quarter?

Twist Bioscience Corp released its earnings results on Aug 03, 2026. The company reported -€0.501 earnings per share for the quarter, missing the consensus estimate of -€0.453 by -€0.048.

Is Twist Bioscience Corp overvalued?

According to Wall Street analysts Twist Bioscience Corp’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Twist Bioscience Corp pay dividends?

Twist Bioscience Corp does not currently pay dividends.

What is Twist Bioscience Corp’s EPS estimate?

Twist Bioscience Corp’s EPS estimate is -0.34.

How many shares outstanding does Twist Bioscience Corp have?

Twist Bioscience Corp has 65,832,420 shares outstanding.

What happened to Twist Bioscience Corp’s price movement after its last earnings report?

Twist Bioscience Corp reported an EPS of -€0.501 in its last earnings report, missing expectations of -€0.453. Following the earnings report the stock price went down -10.04%.

Which hedge fund is a major shareholder of Twist Bioscience Corp?

Currently, no hedge funds are holding shares in DE:0ME

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Twist Bioscience Stock Smart Score

Neutral

Fundamentals

Return on Equity

-29.89%

Trailing 12-Months

Asset Growth

4.48%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Twist Bioscience Corp

Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.

Twist Bioscience (0ME) Earnings & Revenues

Historic Earnings Reports

0ME Company Deck

0ME Earnings Call

Q3 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveyed a broadly positive operational and commercial narrative: record revenue ($118.4M, +23% YoY), strong DSPS and therapeutics growth (+39% and +49% YoY respectively), improved gross margin (52.8%, +120 bps sequential), operational efficiency gains, and raised full-year guidance. Management reiterated confidence in triple-digit AI-enabled order growth for FY2026 and FY2027 and guided to adjusted EBITDA breakeven in Q4. Near-term risks include a Q3 adjusted EBITDA loss (~$11.3M), elevated OpEx, modest cash decline, some underperforming segments, and timing/visibility risks around order-to-revenue conversion and competitive dynamics. Overall, positive momentum and structural improvements outweigh the near-term profitability and timing challenges.View all DE:0ME earnings summaries

0ME Stock 12 Month Forecast

Average Price Target

€141.55

▲(9.35% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"20":"€20","193":"€193","63.25":"€63.3","106.5":"€106.5","149.75":"€149.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":192.4898526,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€192.49</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":141.54718928399998,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€141.55</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40.2885738,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€40.29</span>\n  </div></div>","useHTML":true}}],"tickPositions":[20,63.25,106.5,149.75,193],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,169.55,171.31460404615385,173.0792080923077,174.84381213846154,176.6084161846154,178.37302023076924,180.13762427692308,181.90222832307694,183.66683236923078,185.4314364153846,187.19604046153847,188.9606445076923,190.72524855384617,{"y":192.4898526,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,169.55,167.3959376372308,165.24187527446153,163.0878129116923,160.9337505489231,158.77968818615383,156.6256258233846,154.47156346061539,152.31750109784616,150.1634387350769,148.00937637230768,145.85531400953846,143.7012516467692,{"y":141.54718928399998,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,169.55,159.6068133692308,149.66362673846155,139.72044010769233,129.77725347692308,119.83406684615386,109.89088021538463,99.9476935846154,90.00450695384616,80.06132032307693,70.1181336923077,60.17494706153846,50.23176043076924,{"y":40.2885738,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.34,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.2,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.98,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.54,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.45,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.04,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.68,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.48,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.18,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.48,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":114.15,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":169.55,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >